Obesity
-
Worcestershire bucks national trend as adult obesity rates decline
New data shows Worcestershire’s adult overweight and obesity rates dropped to 63%, defying a national upward trend through targeted community-led health initiatives.
-
Novo Nordisk Targets Australian Market for Wegovy Pill Expansion
Following its UK debut, Novo Nordisk is eyeing an Australian launch for its oral weight-loss drug Wegovy, pending local regulatory approval.
-
Intermittent Fasting Not Superior for Weight Loss, Review Finds
A major Cochrane review of 22 clinical trials indicates that intermittent fasting is no more effective for weight loss in overweight adults than.
-
Intermittent Fasting No More Effective for Weight Loss, New Review Finds
A major new review casts doubt on intermittent fasting’s superior efficacy for weight loss, comparing it to other dietary approaches and raising questions about long-term health management.
-
Novo Nordisk CEO Unveils Aggressive Strategy to Reclaim GLP-1 Market Lead, Targets 2 Billion People
Novo Nordisk’s new CEO Maziar Mike Doustdar outlines a bold three-pronged strategy for 2026, aiming to reclaim market dominance in the GLP-1 obesity drug sector from rival Eli Lilly. The plan focuses on commercial execution, pipeline progression, and a return…
-
Wegovy Set for PBS Listing: A New Dawn for Affordable Weight Loss in Australia
Australia’s government plans to subsidize Wegovy under the Pharmaceutical Benefits Scheme (PBS), making the crucial weight-loss medication significantly more affordable for eligible patients with severe obesity and cardiovascular disease. This move could transform access to treatment for thousands, despite potential…
-
Weight Loss Medication in 2025: Safety, Shortages, and the Surge of Counterfeits
As breakthrough weight loss drugs reshape obesity treatment, 2025 brings new hope—and new risks. From FDA-approved injections to counterfeit dangers and WHO warnings about limited access, this deep dive reveals the realities behind the headlines.
-
Ozempic and GLP-1 Drugs: New Safety Warnings on Mental Health and Contraception Risks
Australian regulators have updated safety warnings for Ozempic and related GLP-1 drugs, citing potential mental health risks and contraceptive effectiveness concerns. While evidence of a direct link is inconclusive, authorities advise caution and closer monitoring for vulnerable patients.
-
Decoding Satiety: Unlocking the Brain’s Appetite Control Mechanism
New Research Identifies Key Neurons That Signal When to Stop Eating, Offering Potential for Obesity Treatment We’ve all experienced that moment when we realize we’ve had enough to eat. But how does our brain know when to stop? Groundbreaking research…
-
Ultra-Processed Foods Linked to Fat Buildup in Muscles and Risk of Osteoarthritis
A new study presented at the Radiological Society of North America’s (RSNA) annual meeting reveals a concerning link between ultra-processed food consumption and increased fat storage in thigh muscles, which could elevate the risk of knee osteoarthritis. Researchers found that…
-
Drinking Water for Weight Loss: A Simple Solution Backed by Science
Recent studies have highlighted the potential of a readily available and cost-free intervention for weight loss: drinking water according to NutritionFacts.org. This seemingly simple act can significantly increase the body’s metabolic rate, leading to increased calorie burning and potentially contributing…